IRIS Accounts Production v25.1.0.734 13187046 Board of Directors 1.5.23 30.4.24 30.4.24 false true false false true false Ordinary A shares 1.00000 Ordinary B Shares 1.00000 Ordinary C shares 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh131870462023-04-30131870462024-04-30131870462023-05-012024-04-30131870462022-04-30131870462022-05-012023-04-30131870462023-04-3013187046ns15:EnglandWales2023-05-012024-04-3013187046ns14:PoundSterling2023-05-012024-04-3013187046ns10:Director12023-05-012024-04-3013187046ns10:PrivateLimitedCompanyLtd2023-05-012024-04-3013187046ns10:SmallEntities2023-05-012024-04-3013187046ns10:AuditExempt-NoAccountantsReport2023-05-012024-04-3013187046ns10:SmallCompaniesRegimeForDirectorsReport2023-05-012024-04-3013187046ns10:SmallCompaniesRegimeForAccounts2023-05-012024-04-3013187046ns10:FullAccounts2023-05-012024-04-3013187046ns10:OrdinaryShareClass12023-05-012024-04-3013187046ns10:OrdinaryShareClass22023-05-012024-04-3013187046ns10:OrdinaryShareClass32023-05-012024-04-3013187046ns10:Director22023-05-012024-04-3013187046ns10:Director32023-05-012024-04-3013187046ns10:RegisteredOffice2023-05-012024-04-3013187046ns5:CurrentFinancialInstruments2024-04-3013187046ns5:CurrentFinancialInstruments2023-04-3013187046ns5:ShareCapital2024-04-3013187046ns5:ShareCapital2023-04-3013187046ns5:RetainedEarningsAccumulatedLosses2024-04-3013187046ns5:RetainedEarningsAccumulatedLosses2023-04-3013187046ns5:CostValuation2023-04-3013187046ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-04-3013187046ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-04-3013187046ns10:OrdinaryShareClass12024-04-3013187046ns10:OrdinaryShareClass22024-04-3013187046ns10:OrdinaryShareClass32024-04-30
REGISTERED NUMBER: 13187046 (England and Wales)















FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2024

FOR

FOOD ALLERGY IMMUNOTHERAPY LIMITED

FOOD ALLERGY IMMUNOTHERAPY LIMITED (REGISTERED NUMBER: 13187046)






CONTENTS OF THE FINANCIAL STATEMENTS
for the Year Ended 30 April 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


FOOD ALLERGY IMMUNOTHERAPY LIMITED

COMPANY INFORMATION
for the Year Ended 30 April 2024







DIRECTORS: Professor A T Fox
Professor G Lack
Professor L G Toit





REGISTERED OFFICE: 10 London Mews
Paddington
London
W2 1HY





REGISTERED NUMBER: 13187046 (England and Wales)





ACCOUNTANTS: Stein Richards
Chartered Accountants
10 London Mews
Paddington
LONDON
W2 1HY

FOOD ALLERGY IMMUNOTHERAPY LIMITED (REGISTERED NUMBER: 13187046)

BALANCE SHEET
30 April 2024

30.4.24 30.4.23
Notes £    £    £   
FIXED ASSETS
Investments 4 1 1

CURRENT ASSETS
Debtors 5 382,909 391,331
Cash at bank 1,444,945 698,866
1,827,854 1,090,197
CREDITORS
Amounts falling due within one year 6 908,381 577,877
NET CURRENT ASSETS 919,473 512,320
TOTAL ASSETS LESS CURRENT
LIABILITIES

919,474

512,321

CAPITAL AND RESERVES
Called up share capital 7 9,000 9,000
Retained earnings 910,474 503,321
SHAREHOLDERS' FUNDS 919,474 512,321

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 23 April 2025 and were signed on its behalf by:





Professor A T Fox - Director


FOOD ALLERGY IMMUNOTHERAPY LIMITED (REGISTERED NUMBER: 13187046)

NOTES TO THE FINANCIAL STATEMENTS
for the Year Ended 30 April 2024

1. STATUTORY INFORMATION

Food Allergy Immunotherapy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements
The financial statements contain information about Food Allergy Immunotherapy Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Turnover
Turnover represents fee income in the year, net of discounts.

Rendering of services

Revenue for providing services is recognised in the period when work is carried out.

Financial instruments
The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities such as trade and other debtors and creditors and loans to related parties.

The basic financial debtors and liabilities as listed above are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future payments / receipts discounted at a market rate of interest. Such instruments are subsequently carried at amortised cost using the effective interest method, less any impairment. An impairment review is undertaken annually at the balance sheet date.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

FOOD ALLERGY IMMUNOTHERAPY LIMITED (REGISTERED NUMBER: 13187046)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 30 April 2024

2. ACCOUNTING POLICIES - continued

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 6 (2023 - 3 ) .

4. FIXED ASSET INVESTMENTS
Other
investments
£   
COST
At 1 May 2023
and 30 April 2024 1
NET BOOK VALUE
At 30 April 2024 1
At 30 April 2023 1

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.4.24 30.4.23
£    £   
Trade debtors 306,664 350,651
Other debtors 76,245 40,680
382,909 391,331

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.4.24 30.4.23
£    £   
Trade creditors 5,674 30,508
Taxation and social security 132,864 109,927
Other creditors 769,843 437,442
908,381 577,877

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30.4.24 30.4.23
value: £    £   
3,000 Ordinary A shares £1 3,000 3,000
3,000 Ordinary B Shares £1 3,000 3,000
3,000 Ordinary C shares £1 3,000 3,000
9,000 9,000